Rahman M F, Nandi A K, Kabir S, Kamal M, Basher M S, Banu L A
Dr Md Fashiur Rahman, Assistant Professor, Department of Dermatology and Venereology, Mymensingh Medical College (MMC), Mymensingh, Bangladesh.
Mymensingh Med J. 2015 Jul;24(3):457-63.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease in early childhood. Atopic dermatitis is familial disease, often coexists with other atopic diseases with multiple risk factors associated with atopic eczema. The disease is more frequent in urban areas compared with rural areas. Changes in nutrition and a decrease in infant breast-feeding and respiratory allergies are contributory factors for the condition. A Randomized Controlled Trial (RCT) was carried to compare the efficacy and safety of Tacrolimus ointment with a topical corticosteroid reference therapy. A total 60 patients aged between 2 to 10 years, having atopic dermatitis for at least one year and comply Hanifin-Rajka criteria were selected using random number table and allocated into study and control groups through randomization. Study group was treated with topical Tacrolimus 0.03% twice daily for three weeks, while the control group was treated with 1% Hydrocortisone acetate for the same period. Both groups had a washed out phase for 2 weeks with a follow up period of 6 weeks. Eczema Area and Severity lndex (EASI) was assessed at baseline and three weeks after treatment. Efficacy was evaluated at each visit by six clinical signs of atopic dermatitis through measurement of the affected surface area and the EASI score in each of four body regions. Before intervention, in study group mean EASI score was 11.29 with a SD of 2.14, while in control group it was 11.05 with a SD of 2.46. Difference was statistically insignificant (p>0.05). At the end of the treatment, in study group mean EASI score was 4.86 with a SD of 1.01, while in control group it was 7.97 with a SD of 1.80. Statistically high significant difference was observed between EASI scores of two groups before and after the treatment (p<0.001). After getting treatment with Tacrolimus, median reduction of EASI score was 56.07 in study group, while getting treatment with Hydrocortisone, median reduction of EASI score was 27.16. Difference was highly significant (p<0.001). It is evidenced that Tacrolimus ointment (0.03%) acts as an effective as well as safe non-steroidal topical therapy for the treatment of dermatitis in paediatric patients.
特应性皮炎(AD)是一种儿童期慢性炎症性皮肤病。特应性皮炎是一种家族性疾病,常与其他特应性疾病共存,有多种与特应性湿疹相关的危险因素。与农村地区相比,该病在城市地区更为常见。营养变化、婴儿母乳喂养减少和呼吸道过敏是导致该病的因素。进行了一项随机对照试验(RCT),以比较他克莫司软膏与外用皮质类固醇对照疗法的疗效和安全性。使用随机数字表选取了总共60名年龄在2至10岁之间、患有特应性皮炎至少一年且符合Hanifin-Rajka标准的患者,并通过随机化将其分为研究组和对照组。研究组每天两次外用0.03%他克莫司,持续三周,而对照组在同一时期外用1%醋酸氢化可的松。两组均有2周的洗脱期和6周的随访期。在基线和治疗三周后评估湿疹面积和严重程度指数(EASI)。每次就诊时通过特应性皮炎的六种临床体征,测量四个身体部位中每个部位的受累表面积和EASI评分来评估疗效。干预前,研究组的平均EASI评分为11.29,标准差为2.14,而对照组为11.05,标准差为2.46。差异无统计学意义(p>0.05)。治疗结束时,研究组的平均EASI评分为4.86,标准差为1.01,而对照组为7.97,标准差为1.80。两组治疗前后的EASI评分之间观察到统计学上的高度显著差异(p<0.001)。使用他克莫司治疗后,研究组EASI评分的中位数降低了56.07,而使用氢化可的松治疗后,EASI评分的中位数降低了27.16。差异非常显著(p<0.001)。证明他克莫司软膏(0.03%)是治疗小儿患者皮炎的一种有效且安全的非甾体外用疗法。